Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ISO
|
|||
| Drug Name |
Bemarituzumab
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 2 | [1] | |
| Company |
Five Prime Therapeutics South San Francisco, CA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.